Efficacy of linezolid against methicillin-resistant or vancomycin-insensitive Staphylococcus aureus in a model of hematogenous pulmonary infection.
We investigated the activities of linezolid, vancomycin, and teicoplanin in a murine model of hematogenous pulmonary infection with Staphylococcus aureus. Our results demonstrate that linezolid clearly reduced bacterial numbers in the methicillin-resistant S. aureus hematogenous infection model and significantly improved the survival rate of immunocompromised mice infected with vancomycin-insensitive S. aureus compared with vancomycin and teicoplanin. The pharmacokinetic profiles also reflected the effectiveness of linezolid.
Yanagihara
Katsunori
K
Second Department of Internal Medicine, Nagasaki University Graduate School of Pharmaceutical Sciences, Japan. kyana-ngs@umin.ac.jp
Kaneko
Yukihiro
Y
Sawai
Toyomitsu
T
Miyazaki
Yoshitsugu
Y
Tsukamoto
Kazuhiro
K
Hirakata
Yoichi
Y
Tomono
Kazunori
K
Kadota
Jun-Ichi
J
Tashiro
Takayoshi
T
Murata
Ikuo
I
Kohno
Shigeru
S
D000081:Acetamides / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000818:Animals; D000900:Anti-Bacterial Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004195:Disease Models, Animal; D000069349:Linezolid; D008297:Male; D016106:Methicillin Resistance; D051379:Mice; D023303:Oxazolidinones / Q000493:pharmacokinetics / Q000627:therapeutic use*; D012141:Respiratory Tract Infections / Q000188:drug therapy / Q000382:microbiology / Q000401:mortality; D013203:Staphylococcal Infections / Q000188:drug therapy / Q000382:microbiology / Q000401:mortality; D013211:Staphylococcus aureus / Q000187:drug effects*; D017334:Teicoplanin / Q000493:pharmacokinetics / Q000627:therapeutic use; D014640:Vancomycin / Q000493:pharmacokinetics / Q000627:therapeutic use*
D000081:Acetamides; D000900:Anti-Bacterial Agents; D023303:Oxazolidinones; D017334:Teicoplanin; D014640:Vancomycin; D000069349:Linezolid